BioSpace News Archive

Crescita Therapeutics Inc., a Canadian commercial dermatology company, is pleased to announce that its President and CEO, Serge Verreault will be presenting at the upcoming Bloom Burton & Co.

ESSA Pharma Inc. announced an abstract on ESSA’s aniten compounds for metastatic castration-resistant prostate cancer has been selected for a moderated poster presentation at the upcoming 2019 American Urological Association Annual Meeting from May 3-6 in Chicago, Illinois.

Vapotherm, Inc. announced that it will release financial results for the first quarter of 2019 after the close of trading on Tuesday, May 7, 2019.

OneTrust, the largest and most widely used dedicated privacy management platform today announced Anthony Nolan, a pioneering charity that saves the lives of people with blood cancer, selected OneTrust for their GDPR and privacy program compliance.

Crop Infrastructure Corp. (CSE: CROP) (OTC: CRXPF) (Frankfurt: 2FR) announced today that it has identified multiple Tenants for a roll out strategy to enter Oklahoma to target the Medical Cannabis market focusing on Cultivation, Extraction and Retail infrastructure.

Advanced Prenatal Therapeutics, Inc. (APT) announced today that the U.S. Food and Drug Administration (FDA) granted a Breakthrough Device Designation for APT’s Targeted Apheresis Column for Preeclampsia (TAC-PE).

ThermoGenesis Corp., a wholly owned subsidiary of Cesca Therapeutics (Nasdaq: KOOL), and a market leader in automated cellular processing, today announced the release of the enhanced X-MINI® CD3 Selection Kit for the research market.

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a key opinion leader (KOL) breakfast symposium focused on the unmet need, treatment landscape and opportunities for selective cyclin-dependent kinase 7 (CDK7) inhibition in ovarian and breast cancers on Wednesday, April 24, 2019

InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) (“InVivo” or the “Company”) today announced the presentation of the twelve-month results from the company’s single-arm INSPIRE study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury)

AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that the Company received central Institutional Review Board (IRB) approval to conduct its NanoKnife® Irreversible Electroporation “Direct IRE Cancer Treatment” clinical study (DIRECT).